

Product Information



Epoxomicin

Item No. 10007806

CAS Registry No.: 134381-21-8

Formal Name: N-acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-[(1S)-3-methyl-1-[[[(2R)-2-methyloxiranyl]carbonyl]butyl]-L-threoninamide

Synonym: BU 4061T


MF: $C_{28}H_{50}N_4O_7$

FW: 554.7

Purity: $\geq 98\%$

Stability: ≥ 1 year at -20°C

Supplied as: A solution in DMSO



Laboratory Procedures

For long term storage, we suggest that epoxomicin be stored as supplied at -20°C . It should be stable for at least one year.

If aqueous stock solutions are required for biological experiments, they can best be prepared by diluting the organic solvent into aqueous buffers or isotonic saline. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

Epoxomicin is a potent anti-tumor agent isolated from *Actinomycetes* that is used as a selective and irreversible inhibitor of the 20S proteasome. It inhibits proteasome activity in cell growth assays with an IC_{50} value of 4 nM and demonstrates potent cytotoxicity against B16-F10, HCT116, and Moser solid tumor cells, as well as P388 and K562 leukemia cells with IC_{50} values ranging from 2-44 nM.^{1,2} By inhibiting osteoblast proteasome activity, epoxomicin stimulates bone formation at concentrations as low as 10 nM.³ Intraperitoneal injection of 1.5 mg/kg epoxomicin given daily for two weeks induces Parkinson's-like symptoms in rats and addition of 100 nM epoxomicin to rat ventral midbrain cultures results in apoptosis specific to dopaminergic neurons.^{4,5} Epoxomicin-induced parkinsonism can be a useful model to examine mechanisms and therapies for the disease.

References

1. Kim, K.B., Myung, J., Sin, N., *et al.* Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: Insights into specificity and potency. *Bioorg. Medicinal Chem. Letters* **9**, 3335-3340 (1999).
2. Hanada, M., Sugawara, K., Kaneta, K., *et al.* Epoxomicin, a new antitumor agent of microbial origin. *J. Antibiotics* **45**(11), 1746-1752 (1992).
3. Garrett, I.R., Chen, D., Gutierrez, G., *et al.* Selective inhibitors of the osteoblast proteasome stimulate bone formation *in vivo* and *in vitro*. *J. Clin. Invest.* **111**(11), 1771-1782 (2003).
4. McNaught, K.St.M., Perl, D.P., Brownell, A.-L., *et al.* Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. *Ann. Neurol.* **56**, 149-162 (2004).
5. Rideout, H.J., Lang-Rollin, I.C.J., Savalle, M., *et al.* Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition. *J. Neurochem.* **93**, 1304-1313 (2005).

Related Products

IU1 - Item No. 10617 • Lactacystin - Item No. 70980 • Clasto-Lactacystin β -lactone - Item No. 70988 • Salinosporamide A - Item No. 10007311 • Salinosporamide B - Item No. 10007563

WARNING: THIS PRODUCT IS FOR LABORATORY RESEARCH ONLY: NOT FOR ADMINISTRATION TO HUMANS. NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

MATERIAL SAFETY DATA

This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Material Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Cayman Chemical Company makes **no warranty or guarantee** of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman warrants only to the original customer that the material will meet our specifications at the time of delivery.

Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have any obligation or liability, whether in tort (including negligence) or in contract, for any direct, indirect, incidental or consequential damages, even if Cayman is informed about their possible existence.

This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees.

Buyer's exclusive remedy and Cayman's sole liability hereunder shall be limited to a refund of the purchase price, or at Cayman's option, the replacement, at no cost to Buyer, of all material that does not meet our specifications.

Said refund or replacement is conditioned on Buyer giving written notice to Cayman within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

For further details, please refer to our Warranty and Limitation of Remedy located on our website and in our catalog.

Copyright Cayman Chemical Company, 03/11/2011

Cayman Chemical

Mailing address

1180 E. Ellsworth Road
Ann Arbor, MI
48108 USA

Phone

(800) 364-9897
(734) 971-3335

Fax

(734) 971-3640

E-Mail

custserv@caymanchem.com

Web

www.caymanchem.com